SAN FRANCISCO, October 3, 2023 — The Scleroderma Research Foundation (SRF), the nation’s largest non-profit funder of scleroderma research, today announced that Boehringer Ingelheim, a leading research-driven biopharmaceutical company, will…
As we start 2022, thank you for inspiring all of us at the SRF to remain laser-focused on our mission—finding a cure for scleroderma. And thanks to the support of our…
ILD Day is here! Lung involvement is very common in patients with systemic scleroderma and may result in interstitial lung disease. Shortness of breath is a common symptom of all…